Literature DB >> 33826063

Lack of association between TREM2 rs75932628 variant and amyotrophic lateral sclerosis.

Vasileios Siokas1,2, Athina-Maria Aloizou1,2, Ioannis Liampas1,2, Zisis Tsouris1,2, Alexios-Fotios A Mentis1,2,3, Grigorios Nasios4, Dimitra Papadimitriou5, Dimitrios P Bogdanos2,6, Georgios M Hadjigeorgiou1,2,7, Efthimios Dardiotis8,9.   

Abstract

Amyotrophic lateral sclerosis (ALS) is a multifactorial neurodegenerative disease. Inflammatory processes are among the mechanisms that are implicated in ALS pathogenesis. The TREM2 rs75932628 T variant may influence the regulatory effect of TREM2 on inflammation. Studies regarding the role of the rs75932628 variant in ALS have yielded inconsistent results, so far. To assess the role of TREM2 rs75932628 on ALS risk. We genotyped 155 patients with sporadic ALS and 155 healthy controls for TREM2 rs75932628. We also merged and meta-analyzed our data with data from previous studies (with a total of 7524 ALS cases and 14,675 controls), regarding TREM2 rs75932628 and ALS. No ALS or healthy subjects carried the TREM2 rs75932628-T variant. Results from meta-analyses (overall approach and sensitivity analyses) yielded no significant results for possible connection between TREM2 rs75932628-T variant and ALS. Based on our results, TREM2 rs75932628 does not seem to play a determining role to the pathophysiology of ALS.

Entities:  

Keywords:  Amyotrophic lateral sclerosis; Genetic variant; Genetics; TREM2; rs75932628

Mesh:

Substances:

Year:  2021        PMID: 33826063     DOI: 10.1007/s11033-021-06312-1

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  41 in total

Review 1.  Epigenetics in amyotrophic lateral sclerosis: a role for histone post-translational modifications in neurodegenerative disease.

Authors:  Seth A Bennett; Royena Tanaz; Samantha N Cobos; Mariana P Torrente
Journal:  Transl Res       Date:  2018-10-12       Impact factor: 7.012

Review 2.  The epidemiology of ALS: a conspiracy of genes, environment and time.

Authors:  Ammar Al-Chalabi; Orla Hardiman
Journal:  Nat Rev Neurol       Date:  2013-10-15       Impact factor: 42.937

Review 3.  The phenotypic variability of amyotrophic lateral sclerosis.

Authors:  Bart Swinnen; Wim Robberecht
Journal:  Nat Rev Neurol       Date:  2014-10-14       Impact factor: 42.937

Review 4.  Amyotrophic lateral sclerosis.

Authors:  Michael A van Es; Orla Hardiman; Adriano Chio; Ammar Al-Chalabi; R Jeroen Pasterkamp; Jan H Veldink; Leonard H van den Berg
Journal:  Lancet       Date:  2017-05-25       Impact factor: 79.321

Review 5.  From animal models to human disease: a genetic approach for personalized medicine in ALS.

Authors:  Vincent Picher-Martel; Paul N Valdmanis; Peter V Gould; Jean-Pierre Julien; Nicolas Dupré
Journal:  Acta Neuropathol Commun       Date:  2016-07-11       Impact factor: 7.801

Review 6.  Amyotrophic Lateral Sclerosis.

Authors:  Robert H Brown; Ammar Al-Chalabi
Journal:  N Engl J Med       Date:  2017-07-13       Impact factor: 91.245

7.  The Role of MicroRNAs in Patients with Amyotrophic Lateral Sclerosis.

Authors:  Efthimios Dardiotis; Athina-Maria Aloizou; Vasileios Siokas; George P Patrinos; Georgia Deretzi; Panayiotis Mitsias; Michael Aschner; Aristidis Tsatsakis
Journal:  J Mol Neurosci       Date:  2018-11-10       Impact factor: 3.444

Review 8.  Decoding ALS: from genes to mechanism.

Authors:  J Paul Taylor; Robert H Brown; Don W Cleveland
Journal:  Nature       Date:  2016-11-10       Impact factor: 49.962

9.  Modelling the effects of penetrance and family size on rates of sporadic and familial disease.

Authors:  Ammar Al-Chalabi; Cathryn M Lewis
Journal:  Hum Hered       Date:  2011-08-12       Impact factor: 0.444

Review 10.  From basic research to the clinic: innovative therapies for ALS and FTD in the pipeline.

Authors:  Rajka Maria Liscic; Antonella Alberici; Nigel John Cairns; Maurizio Romano; Emanuele Buratti
Journal:  Mol Neurodegener       Date:  2020-06-01       Impact factor: 14.195

View more
  4 in total

Review 1.  Microglial TREM2 in amyotrophic lateral sclerosis.

Authors:  Manling Xie; Shunyi Zhao; Dale B Bosco; Aivi Nguyen; Long-Jun Wu
Journal:  Dev Neurobiol       Date:  2021-12-18       Impact factor: 3.964

Review 2.  Imaging immunological processes from blood to brain in amyotrophic lateral sclerosis.

Authors:  Sandra Amor; Erik Nutma; Manuel Marzin; Fabiola Puentes
Journal:  Clin Exp Immunol       Date:  2021-09-21       Impact factor: 4.330

3.  Lack of an association between SCFD1 rs10139154 polymorphism and amyotrophic lateral sclerosis.

Authors:  Vasileios Siokas; Athina-Maria Aloizou; Ioannis Liampas; Christos Bakirtzis; Grigorios Nasios; Konstantinos Paterakis; Markos Sgantzos; Dimitrios P Bogdanos; Demetrios A Spandidos; Aristidis Tsatsakis; Panayiotis D Mitsias; Efthimios Dardiotis
Journal:  Mol Med Rep       Date:  2022-03-02       Impact factor: 2.952

Review 4.  Pathophysiological Underpinnings of Extra-Motor Neurodegeneration in Amyotrophic Lateral Sclerosis: New Insights From Biomarker Studies.

Authors:  David Reyes-Leiva; Oriol Dols-Icardo; Sonia Sirisi; Elena Cortés-Vicente; Janina Turon-Sans; Noemi de Luna; Rafael Blesa; Olivia Belbin; Victor Montal; Daniel Alcolea; Juan Fortea; Alberto Lleó; Ricard Rojas-García; Ignacio Illán-Gala
Journal:  Front Neurol       Date:  2022-01-18       Impact factor: 4.003

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.